$3.49
4.38%
NYSE, Sep 29, 03:21 pm EDT. Market open.
ISIN
US30050B1017
Symbol
EVH

Evolent Health Inc Class A Target price 2026 - Analyst rating & recommendation

Evolent Health Inc Class A Classifications & Recommendation

Buy
79%
Hold
21%

Evolent Health Inc Class A Price Target

Target Price $6.12
Price $3.65
Potential
Number of Estimates 15
15 Analysts have issued a price target Evolent Health Inc Class A 2027 . The average Evolent Health Inc Class A target price is $6.12. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 19 analysts: 15 Analysts recommend Evolent Health Inc Class A to buy, 4 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Evolent Health Inc Class A stock has an average upside potential 2027 of . Most analysts recommend the Evolent Health Inc Class A stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2031

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Billion $ 1.88 2.65
26.56% 41.45%
EBITDA Margin 5.59% 4.86%
23.37% 13.09%
Net Margin -30.88% 0.83%
744.23% 102.69%

17 Analysts have issued a sales forecast Evolent Health Inc Class A 2026 . The average Evolent Health Inc Class A sales estimate is

$2.7b
unlock
. This is
26.56% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$2.8b 33.67%
unlock
, the lowest is
$2.5b 16.83%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $1.9b 26.56%
2026
$2.7b 41.45%
unlock
2027
$3.3b 24.49%
unlock
2028
$3.7b 12.17%
unlock
2029
$4.1b 11.63%
unlock
2030
$4.7b 13.68%
unlock
2031
$5.9b 24.67%
unlock

17 Analysts have issued an Evolent Health Inc Class A EBITDA forecast 2026. The average Evolent Health Inc Class A EBITDA estimate is

$129m
unlock
. This is
60.45% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$142m 76.37%
unlock
, the lowest is
$121m 50.09%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $105m 9.40%
2026
$129m 22.90%
unlock
2027
$158m 22.25%
unlock
2028
$183m 15.77%
unlock
2029
$229m 25.25%
unlock
2030
$270m 18.03%
unlock
2031
$298m 10.51%
unlock

EBITDA Margin

2025 5.59% 23.37%
2026
4.86% 13.09%
unlock
2027
4.77% 1.85%
unlock
2028
4.92% 3.14%
unlock
2029
5.53% 12.40%
unlock
2030
5.74% 3.80%
unlock
2031
5.09% 11.32%
unlock

17 Evolent Health Inc Class A Analysts have issued a net profit forecast 2026. The average Evolent Health Inc Class A net profit estimate is

$22.0m
unlock
. This is
104.30% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$31.9m 106.25%
unlock
, the lowest is
$9.9m 101.94%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $-579m 520.01%
2026
$22.0m 103.79%
unlock
2027
$45.0m 104.82%
unlock
2028
$54.5m 21.13%
unlock
2029
$79.7m 46.14%
unlock
2030
$94.5m 18.58%
unlock

Net Margin

2025 -30.88% 744.23%
2026
0.83% 102.69%
unlock
2027
1.36% 63.86%
unlock
2028
1.47% 8.09%
unlock
2029
1.93% 31.29%
unlock
2030
2.01% 4.15%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2031

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ -5.07 0.20
525.93% 103.94%
P/E 18.72
EV/Sales 0.48

17 Analysts have issued a Evolent Health Inc Class A forecast for earnings per share. The average Evolent Health Inc Class A EPS is

$0.20
unlock
. This is
104.41% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$0.28 106.17%
unlock
, the lowest is
$0.09 101.98%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-5.07 525.93%
2026
$0.20 103.94%
unlock
2027
$0.40 100.00%
unlock
2028
$0.48 20.00%
unlock
2029
$0.71 47.92%
unlock
2030
$0.84 18.31%
unlock

P/E ratio

Current -0.80 85.54%
2026
18.72 2,428.36%
unlock
2027
9.14 51.18%
unlock
2028
7.54 17.51%
unlock
2029
5.16 31.56%
unlock
2030
4.35 15.70%
unlock

Based on analysts' sales estimates for 2026, the Evolent Health Inc Class A stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.60 23.08%
2026
0.48 20.67%
unlock
2027
0.38 19.66%
unlock
2028
0.34 10.85%
unlock
2029
0.31 10.41%
unlock
2030
0.27 12.05%
unlock
2031
0.22 19.77%
unlock

P/S ratio

Current 0.20 58.91%
2026
0.16 20.99%
unlock
2027
0.12 19.68%
unlock
2028
0.11 10.81%
unlock
2029
0.10 10.41%
unlock
2030
0.09 12.12%
unlock
2031
0.07 19.73%
unlock

Current Evolent Health Inc Class A Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JP Morgan
Locked
➜
Locked
Locked Aug 18 2026
TD Cowen
Locked
➜
Locked
Locked Aug 17 2026
Truist Securities
Locked
➜
Locked
Locked Aug 12 2026
Citigroup
Locked
➜
Locked
Locked Aug 11 2026
Canaccord Genuity
Locked
➜
Locked
Locked Aug 10 2026
TD Cowen
Locked
➜
Locked
Locked Jul 28 2026
Citigroup
Locked
➜
Locked
Locked Jul 23 2026
Analyst Rating Date
Locked
JP Morgan:
Locked
➜
Locked
Aug 18 2026
Locked
TD Cowen:
Locked
➜
Locked
Aug 17 2026
Locked
Truist Securities:
Locked
➜
Locked
Aug 12 2026
Locked
Citigroup:
Locked
➜
Locked
Aug 11 2026
Locked
Canaccord Genuity:
Locked
➜
Locked
Aug 10 2026
Locked
TD Cowen:
Locked
➜
Locked
Jul 28 2026
Locked
Citigroup:
Locked
➜
Locked
Jul 23 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today